Lunai Bioworks Inc. — fact timeline

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(b)(2)).

“April 28, 2026 of an additional staff determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC regarding compliance with Nasdaq Listing Rule 5550(b)(2). The soliciting material and related disclosures included in the Original Report under the captions “The Special Meeting and the Proposals Being Voted On,” “Additional Information and Where to Find It” and “Participants in the Solicitation,” are no longer applicable because the Special Meeting has been held and the proposals submitted to a vote of stockholders thereat have been acted upon. Except as expressly se”

Lunai Bioworks Inc. issued preferred stock for $20,000,000.

“of the Company, the holders of the Series B Preferred Stock are entitled to a senior liquidation preference equal to the aggregate Stated Value of the Series B Preferred Stock ($20,000,000), and to the extent that, upon receipt of the Stockholder Approval, the Series B Preferred Stock will become convertible into shares of common stock at a fixed Conversion Price”

Lunai Bioworks Inc. completed an acquisition involving Neurobridge IP Holdings Incorporated for $20,000,000 aggregate stated value of Series B Convertible Preferred Stock (closed 2026-05-01).

“nto an Agreement and Plan of Merger (the “Merger Agreement”) with Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger”

Lunai Bioworks Inc. entered into Merger Agreement (effective 2026-05-01).

“The foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current”

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S”

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S”

Lunai Bioworks Inc. issued an aggregate of 1,433,621 additional shares of common stock of warrant to three of the Company's holders of secured promissory notes for part of the debt exchange.

“common stock purchase warrants to acquire an aggregate of 1,433,621 additional shares of common stock (the “Warrants”)”

Lunai Bioworks Inc. issued an aggregate of 3,909,293 shares of common stock to three of the Company's holders of secured promissory notes for cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest.

“Pursuant to the Debt Exchange Agreements, the Holders agreed to cancel and extinguish an aggregate of $828,770.14 of outstanding principal and accrued interest owed under the Investor Notes in exchange for an aggregate of 3,909,293 shares of the Company’s common stock”

Lunai Bioworks Inc. entered into Acquisition Agreement with Clemann Group, SAS valued at $20.0 million (effective 2026-03-26).

“On March 26, 2026, the Company entered into a binding agreement (the “Acquisition Agreement”) with Clemann Group, SAS, or its assignee (the “Seller”), pursuant to which the Company agreed to acquire certain blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets (the “Transaction”).”

Lunai Bioworks Inc. entered into Debt Exchange Agreements with three of the Company’s holders of secured promissory notes valued at $828,770.14 (effective 2026-03-24).

“On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”).”

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding other.

“February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. A”

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“February 6, 2026, Lunai Bioworks, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below $1.00 per share for 30 consecutive business days from December 23, 2025 through February 5”

Lunai Bioworks Inc. entered into At-the-Market Sales Agreement with Dawson James Securities, Inc. valued at up to $11.70 million (effective 2025-12-02).

“On December 2, 2025, Lunai Bioworks, Inc. (the “Company”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell (the “Offering”) shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $11.70 million, from time to time through the Sales Agent as the Company’s sales agent.”

Lunai Bioworks Inc. issued 1,044,444 three-year warrants, executable after sixty (60) days of warrant to an accredited investor for included in aggregate gross proceeds of $3,133,333.

“and 1,044,444 three-year warrants, executable after sixty (60) days (the “Warrants”) for aggregate gross proceeds of $3,133,333”

Lunai Bioworks Inc. issued 3,133,333 shares of its common stock of common stock to an accredited investor for $1.00 per share.

“On November 24, 2025, Lunai Bioworks Inc. (“Lunai” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to sell, and the Investor agreed to purchase, in a private placement, 3,133,333 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $1.00 per share”

Lunai Bioworks Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).

“otifying the Company that it was no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year.”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“October 27, 2025, Lunai Bioworks (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $35 million minimum Market Value of Listed Securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) for Capital Market. The Notice stated that the Company’s MVLS had been below $35 million for the previous 30 consecutive business days, and that, in accordance with Nasdaq rules, the Company has a period of 180 calendar days, or until April 27”

Lunai Bioworks Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“13(a) of the Exchang e Act. ☐ Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 15, 2025, Lunai Bioworks (the “Company”) received a Notice from the NASDAQ Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2). On April 14, 2025, the NASDAQ staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the NASDAQ Stock Market. Since then, the staff of NASDAQ has determin”

Lunai Bioworks Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, par value unchanged, effective September 29, 2025; authorized shares unchanged at 350,000,000 (effective 2025-09-29).

“On September 18, 2025, Lunai Bioworks, Inc. (the “ Company ”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025 (the “ Reverse Stock Split ”).”

Lunai Bioworks Inc. announced a impairment.

“management determined on September 2, 2025 that a material impairment of assets has occurred. The Company expects to record an impairment charge for the quarter ending September 30, 2025, however, is unable to make a good faith estimate of the same or the cash expenditures resulting from the impairment charge, if any, at the time of this filing.”

Lunai Bioworks Inc.: Changed corporate name from Renovaro Inc. to Lunai Bioworks Inc (effective 2025-08-20).

“On August 18, 2025, Renovaro Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to change its corporate name from ”Renovaro Inc.” to ”Lunai Bioworks Inc.” (the “Name Change”). The Name Change became effective on August 20, 2025.”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“July 7, 2025, Renovaro Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. On August 5, 2025, the Company received written confirmation from Nasdaq that it has accepted the Company’s plan to regain compliance and has granted an extension until October 31, 2025, for the Company to hold its annual meeting of shareholders. The Company intends to hold the ann”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“July 7, 2025, Renovaro Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year. The Company did not hold its annual meeting of shareholders within twelve months of the end of its fiscal year ended June 30, 2024, and therefore did not satisfy this requirement. Pursuant to Nasdaq Listi”

Maurice van Tilburg resigned as Chief Executive Officer of GEDi Cube B.V. at Lunai Bioworks Inc..

“On May 30, 2025, Maurice van Tilburg notified Renovaro Inc. (the “Company”) of his intent to resign from the office of Chief Executive Officer of GEDi Cube B.V., a wholly-owned indirect subsidiary of the Company, which resignation was effective May 30, 2025.”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 14, 2025, Renovaro Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market an”

Simon Tarsh was removed as Interim Chief Financial Officer at Lunai Bioworks Inc..

“In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.”

Nathen Fuentes was appointed as Chief Financial Officer at Lunai Bioworks Inc..

“Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.”

Maurice van Tilburg was appointed as Chief Executive Officer of GEDi Cube B.V. at Lunai Bioworks Inc..

“On December 30, 2024, the Board appointed Maurice van Tilburg, age 53, as Chief Executive Officer of GEDi Cube B.V.”

Francois Binette PhD resigned as Chief Operating Officer at Lunai Bioworks Inc..

“On November 15, 2024, Francois Binette PhD, Renovaro Inc.’s Chief Operating Officer, tendered his resignation as Chief Operating Officer, effective November 22, 2024.”

Mark Collins was appointed as Director at Lunai Bioworks Inc..

“Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined”

Douglas Calder was appointed as Director at Lunai Bioworks Inc..

“Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined”

James McNulty was appointed as Director at Lunai Bioworks Inc..

“Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined”

Maurice van Tilburg was appointed as Director at Lunai Bioworks Inc..

“Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined”

David Weinstein was appointed as Director at Lunai Bioworks Inc..

“Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined”

Rene Sindlev resigned as Chairman of the Board at Lunai Bioworks Inc..

“On October 15, 2024, Rene Sindlev resigned as the Chairman of the Board of the Company, effective immediately.”

Carol Brosgart resigned as Director at Lunai Bioworks Inc..

“On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.”

Jayne McNicol resigned as Director at Lunai Bioworks Inc..

“On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.”

Gregg Alton resigned as Lead Independent Director at Lunai Bioworks Inc..

“On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.”

James Sapirstein resigned as Director at Lunai Bioworks Inc..

“On October 12, 2024, James Sapirstein a member of the Board formally advised the Board of the Company that he was resigning from the Board, effective immediately.”

Karen Brink resigned as Director at Lunai Bioworks Inc..

“On October 12, 2024, Karen Brink resigned as a director on the Board of the Company, effective immediately.”

Ruud Hendriks resigned as Director at Lunai Bioworks Inc..

“On the same date, Ruud Hendriks resigned as a director on the Board of the Company, effective immediately.”

Avram Miller resigned as Director at Lunai Bioworks Inc..

“On October 11, 2024, Avram Miller resigned as a director on the Board of the Company, effective immediately.”

Leni Boeren resigned as Director and Chair of Special Litigation Committee at Lunai Bioworks Inc..

“On June 27, 2024, Leni Boeren provided notice of her resignation as a member of the Board of Directors of Renovaro Inc. (the “ Company ”), with such resignation being effective June 27, 2024.”

Ms. Puche departed as Chief Financial Officer at Lunai Bioworks Inc..

“Ms. Puche, the Company’s outgoing Chief Financial Officer, said: “After more than 5 years at the Company, I am ready for a new phase in my life.”

Simon Tarsh was appointed as Interim Chief Financial Officer at Lunai Bioworks Inc..

“The board of directors (the “Board”) of Renovaro Inc. (the “Company”) appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024.”

Lunai Bioworks Inc. terminated License Agreement with Weird Science LLC (effective 2024-03-01).

“On March 1, 2024, Renovaro Inc. (the “Company”) received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the “License Agreement”).”

Luisa Puche resigned as Chief Financial Officer at Lunai Bioworks Inc..

“Luisa Puche tendered her resignation as Chief Financial Officer of Renovaro Inc. (the “Company”), effective as of March 21, 2024.”

Lunai Bioworks Inc.: Amended certificate of incorporation to change corporate name from Renovaro Biosciences Inc. to Renovaro Inc (effective 2024-02-13).

“In connection with the closing of the Transaction, on February 13, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation (the “Name Change Amendment”) to change its corporate name from “Renovaro Biosciences Inc.” to “Renovaro Inc.”, effective immediately.”

Lunai Bioworks Inc. completed an acquisition involving GEDi Cube Intl Ltd. for 70,834,183 shares of common stock plus Earnout Shares (closed 2024-02-13).

“collectively, the “GEDi Cube Shares”) in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller’s pro rata percentage of an aggregate of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”), which represents the 67,224,089 shares of Common Stock issued and outstanding as of the”

Lunai Bioworks Inc. amended Second Amendment to Stock Purchase Agreement with GEDi Cube Intl Ltd. valued at Amendment to Stock Purchase Agreement to increase number of directors from nine to ten and adjust in (effective 2024-02-09).

“On February 9, 2024, the parties to the Stock Purchase Agreement entered into a Second Amendment to Stock Purchase Agreement (the “Amendment”), pursuant to which the parties amended the Stock Purchase Agreement to increase (i) the number of directors comprising the Company’s Board of Directors (the “Board”) effective upon the Closing from nine to ten individuals; (ii) the number of directors to be designated by the Company to serve on the Board effective as of the Closing from four to five individuals; and (iii) the number of such directors designated by the Company who are required to qualify as an “independent director” under Listing Rule 5605(a) of the Nasdaq Stock Market from three to four individuals.”